U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Voriconazole Tablets, Powder for Oral Suspension, Injection
  1. Development Resources

Voriconazole Tablets, Powder for Oral Suspension, Injection

Recognized Interpretive Criteria

 

Minimum Inhibitory Concentrations
(mcg/mL)

Disk Diffusion
(zone diameters in mm)

Pathogen

S

I

R

S

I

R

Aspergillus fumigatus*M38M51S standard is recognized

-

-

-

Candida albicansM27M44S standard is recognizedM27M44S standard is recognized
Candida kruseiM27M44S standard is recognizedM27M44S standard is recognized
Candida parapsilosisM27M44S standard is recognizedM27M44S standard is recognized
Candida tropicalisM27M44S standard is recognizedM27M44S standard is recognized

S = Susceptible; I = Intermediate; R = Resistant

For C. glabrata and voriconazole, current data are insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome.

*Interpretive breakpoints were derived from a collection of sequence-confirmed isolates of A. fumigatus sensu stricto and are not applicable to other members of the A. fumigatus species complex.

Back to Top